Last reviewed · How we verify

Avonex/Zocor — Competitive Intelligence Brief

Avonex/Zocor (Avonex/Zocor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination of interferon and statin. Area: Neurology (MS) and Cardiovascular.

marketed Combination of interferon and statin Interferon beta receptor (Avonex); HMG-CoA reductase (Zocor) Neurology (MS) and Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Avonex/Zocor (Avonex/Zocor) — University of North Carolina. This is a combination of two separate marketed drugs: Avonex (interferon beta-1a) which modulates immune response in multiple sclerosis, and Zocor (simvastatin) which inhibits HMG-CoA reductase to lower cholesterol.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Avonex/Zocor TARGET Avonex/Zocor University of North Carolina marketed Combination of interferon and statin Interferon beta receptor (Avonex); HMG-CoA reductase (Zocor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination of interferon and statin class)

  1. University of North Carolina · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Avonex/Zocor — Competitive Intelligence Brief. https://druglandscape.com/ci/avonex-zocor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: